Grant RDF
pages:- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- more...
- A Randomized, Double-Blind, Placebo-Controlled, Phase 111 Trial of 2 Regimens of Telaprevir (With and Without Delayed.
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of Abt-494
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and Chp (A+Chp) Versus Chop........
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With
- A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment
- A Randomized, Double-Blind, Placebo-Controllstudy to Evaluate Te Efficacy and Safety of Abt-450 /Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
- A Randomized, Double-Blind-Parallel-Group, Multicenter Studyto Evaluate the Retention Rate, Efficacy, Safety,......
- A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase Ii.5 Study of Saracatinib (Azd0530
- A Randomized, Double-Bline, Placebo-Controlled, Crossover Study to Compare the Efficacy & Safety of Carisbamate Vs....
- A Randomized, Doublie-Blind, Placebo-Controlled, Multicenterparallel-Group Phase III, Study to Determine the Efficacy
- A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept...........
- A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patie
- A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of Amg-145 Treatment On...
- A Randomized, Multicenter Study of First Line Ambrisentan and Tadalafil Combination Therapy in Subjects With..........
- A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity.......
- A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity.......
- A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks of Treatment With D
- A Randomized, Multicenter, Double-Blind, Placebo-Controlled,Parallel-Grouop, 24-Week, Pilot Study to Assess the Efficacy
- A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine...
- A Randomized, Multicenter, Phase III Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a . . .
- A Randomized, Open Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed Dose Combination...
- A Randomized, Open-Label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone in Transplant-Ineligible....
- A Randomized, Open-Label Study to Compare the Reate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recip
- A Randomized, Open-Label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens With a Tacrolimus
- A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)
- A Randomized, Open-Label, 2-Period Crossover Study to Assess the Bioequivalence of One 150 Mg Risedronate Tablet Versus
- A Randomized, Open-Label, 3-Period Crossover to Determine Bioavailability of Moa-728 in Subjects on Stable Methadone Mai
- A Randomized, Open-Label, Comparative, Multi-Center, Trial to Evaluate Contraceptive Efficacy, Cycle Control.
- A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12, or 24 Weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus infection
- A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12, or 24 Weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus infection